PSA doubling time is often used to determine recurrence of prostate cancer after radical prostatectomy and to time the initiation of salvage therapy. PSA doubling time was assessed in 394 men from the CaPSURE registry who had biochemical recurrence (BCR) after prostatectomy, using the ultrasensitive (<0.2 ng/ml) and standard (>0.2 ng/ml) ranges. Median ultrasensitive doubling time was 11.9 months, compared with 240 months in the standard range, and agreement between the two measurements was poor (weighted Cohen's kappa score of 0.04). Ultrasensitive measurements potentially overestimate the likelihood of BCR.
ORIGINAL RESEARCH PAPER
Reese, A. C. et al. Poor agreement of prostate specific antigen doubling times calculated using ultrasensitive versus standard prostate specific antigen values: important impact on risk assessment. J. Urol. 186, 2228–2232 (2011)
Rights and permissions
About this article
Cite this article
Ultrasensitive versus standard PSA value for doubling times. Nat Rev Urol 9, 2 (2012). https://doi.org/10.1038/nrurol.2011.200
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2011.200
